Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerTalia Golan, Hedy L. Kindler, Pascal Hammel et al.|New England Journal of Medicine|2019Cited by 2.2k
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Mitesh J. Borad et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transitionPaul Roepman, Iris Simón, Andreas Schlicker et al.|International Journal of Cancer|2013Cited by 350
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Jia Fan et al.|The Lancet Oncology|2023Cited by 243
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerHedy L. Kindler, Talia Golan, Pascal Hammel et al.|Journal of Clinical Oncology|2022Cited by 224